These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3981712)

  • 1. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.
    Lin BJ; Chen KK; Chen MT; Chang LS
    Urology; 1994 Jun; 43(6):834-7. PubMed ID: 8197647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy.
    Klugo RC; Farah RN; Cerny JC
    Urology; 1981 Jan; 17(1):49-50. PubMed ID: 7456197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist.
    Kitahara S; Yoshida K; Ishizaka K; Kageyama Y; Kawakami S; Tsujii T; Oshima H
    Endocr J; 1997 Aug; 44(4):527-32. PubMed ID: 9447285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy.
    Geller J; Albert JD; Nachtsheim DA; Loza D
    J Urol; 1984 Oct; 132(4):693-6. PubMed ID: 6471215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of giant prostate cancer].
    Fujimoto Y; Yamaha M; Maeda S; Takeuchi T; Ito Y; Kuriyama M; Ban Y; Nishiura T
    Hinyokika Kiyo; 1984 Jul; 30(7):925-30. PubMed ID: 6542303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma.
    Russo P; Liguori G; Heston WD; Huryk R; Yang CR; Fair WR; Whitmore WF; Herr HW
    Cancer Res; 1987 Nov; 47(22):5967-70. PubMed ID: 3664500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma testosterone in patients receiving diethylstilbestrol.
    Beck PH; McAnich JW; Goebel JL; Stutzman RE
    Urology; 1978 Feb; 11(2):157-60. PubMed ID: 628992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic prostate cancer. Factors that influence treatment selection and methods to increase acceptance of orchiectomy.
    Merrill DC
    Urology; 1988 Nov; 32(5):408-12. PubMed ID: 3188303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoblastic response to successful treatment of metastatic cancer of the prostate.
    Pollen JJ; Shlaer WJ
    AJR Am J Roentgenol; 1979 Jun; 132(6):927-31. PubMed ID: 108971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
    van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
    J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changes in the binding capacity of testosterone-oestradiol binding globulin (TeBG) following castration and DES-D administration in patients with prostatic carcinoma.
    Usui T; Sagami K; Kitano T; Nihira H; Miyachi Y
    Urol Res; 1982; 10(3):119-22. PubMed ID: 6890254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of endocrine treatment on prostatic blood flow in patients with prostatic adenocarcinoma.
    Toma H; Nakamura R; Onitsuka S; Goya N; Nakazawa H
    J Urol; 1988 Jul; 140(1):91-5. PubMed ID: 3132563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer.
    Takezawa Y; Nakata S; Kobayashi M; Kosaku N; Fukabori Y; Yamanaka H
    Scand J Urol Nephrol; 2001 Sep; 35(4):283-7. PubMed ID: 11676353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
    Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.